Plymouth Meeting, PA – June 15, 2015: CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, today announced the introduction of TrialMax ConMed™, an eDiary-based solution designed to enhance the real-time collection of concomitant medication data from patients in clinical trials. Today, sponsors commonly wait for a patient's site visit in order to enter concomitant medication data into electronic data capture (EDC) systems. This can be problematic as it relies on the patient's ability to recall all the different medications and doses they have taken between visits. TrialMax ConMed makes it simple for patients to report medications that they are taking alongside a study drug in real-time. The intuitive solution not only enhances patient safety and the accuracy of the resulting regulatory submission, but will ensure sites and sponsors achieve high-quality information on a patient's complete medication list for the duration of a clinical trial.
Although difficult to capture, accurate concomitant medication data is increasingly required by regulators for a more complete assessment of the study drug. For example, if an oncology study requires the identification of any pain medication that a patient is taking, patients need to be able to provide their clinician with information on any prescribed and over-the-counter pharmaceuticals that they use. TrialMax ConMed allows patients to select from a predefined list of commonly taken medications or enter a new drug into their TrialMax Touch® eDiary electronically. With access to TrialManager®, CRF Health’s online patient management portal, investigators are alerted to new medication entries to allow them to assess the completeness and accuracy of the data and correct as appropriate. Easy-to-use for both sites and patients, TrialMax ConMed ensures users remain compliant and continue to input new medication details throughout a study.
"In the difficult work of understanding the impact of a new treatment, tracking a patient's intake of non-study medication is becoming an increasingly important regulatory requirement and we recognize that it is a challenge when this type of information is only being provided during intermittent site visits”, comments Paul O'Donohoe, Director, Health Outcomes, CRF Health. "TrialMax ConMed makes it easy for patients to contribute real-time medication information in a way that is both accurate and does not add an additional layer of burden, while minimizing the potential for human error when trying to recall medications and doses at site appointments. At the same time we can ensure that study teams are prompted to review any changes, bringing new awareness of the use of concomitant medication in clinical trials."
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.